VAERS Explorer
Back to explore

Report #2890366

Received Mar 23, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
Recovered
Unknown
Vaccinated
Onset
Days to onset
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.1UnknownPO / MO

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Patient received first dose of Vivotif and did not take the remaining three doses for couple of weeks; Case reference number US-BN-2024-002456 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV24-2319) on 10-Sep-2024 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at a dose of capsule, orally, for typhoid Immunization. As reported, the patient did not resume taking the rest three doses and the reporter believed that it had been a couple of weeks since the patient took the first dose of Vivotif (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240910-ca5f15 to US-BAVARIAN NORDIC A/S-US-BN-2024-002456, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown age and gender did not resume taking the rest three doses, and the reporter believed that it had been a couple of weeks since the patient took the first dose of Vivotif for typhoid Immunization, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown age and gender did not resume taking the rest three doses, and the reporter believed that it had been a couple of weeks since the patient took the first dose of Vivotif for typhoid Immunization, which is considered as incomplete course of vaccination. It was unknown if the patient experienced any adverse event due to Vivotif. Incomplete course of vaccination is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.

Medical history

Comments: None.